Specifically, the regulation of the immune system through immune checkpoint blockade (ICB), most notably via cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1), is the most clinically advanced type of immunotherapy and is approved for multiple cancers. This evidence concerns the gene CTLA4 and cancer.